17-Acetylaphidicolin was 10-fold weaker and two derivatives lacking hydroxyl groups at the 16 and 17 positions were 100-fold weaker than aphidicolin as inhibitors of DNA polymerase a from HeLa and Chinese hamster ovary cells.
INTRODUCTION
Aphidicolin [1] is a potent inhibitor of eukaryotic DNA polymerase a. The enzyme from sea urchin embryos (1), rat liver (2) and cultured cells, e.g. HeLa (3, 4) and KB (5) , is highly sensitive to the drug (Ki ca. 0.5 pM).
The recently described DNA polymerase 6, derived both from primary mammalian tissues (6) (7) (8) and from CV-1 cells (9) , has also been reported to be equally sensitive to 1. Although aphidicolin is selective with respect to the other eukaryotic and bacterial DNA polymerases, it does inhibit the DNA polymerases encoded by Herpes simplex type 1 and vaccinia viruses (10) and the a-like DNA polymerases of yeast (11) and plant cells (12) .
The mechanism of action of 1 on purified DNA polymerase a is unknown, but its effect has most often been reported to be competitive with dCTP and noncompetitive with the other dNTP substrates (1, 5, 10, 13) , a result also observed with sensitive viral (10) and plant (12) polymerases. We have been intrigued by the spectrum of polymerases sensitive to aphidicolin, by the competitive nature of its action, and by the apparent lack of structural similarity between it and dCTP or any other dNTP.
The hydroxyl groups of aphidicolin [1] are situated at opposite ends of a rigid hydrophobic cylindrical structure, and superficially resemble pairs of oxygens in a deoxyribose ring.
As a first step in understanding the mechanism of aphidicolin, we sought to measure the effects of changes in its hydroxyl groups on inhibitory activity. Recently, two naturally occurring derivatives of 1, 17-acetylaphidicolin [2] and 3-deoxyaphidicolin were reported to inhibit sea urchin DNA polymerase a with potencies similar to that of the parent compound (14) .
In contrast, a recent paper claimed that 2, among other semisynthetic aphidicolin derivatives, did not inhibit DNA polymerase a from KB cells (15) . We Compounds. Aphidicolin [1] was obtained from the Pharmaceuticals Division, Imperial Chemical Industries Ltd. and from the Natural Products Branch, National Cancer Institute.
Compound 6 was a gift from Imperial Chemical Industries Ltd., and the other derivatives, 2-5 and 7, were synthesized and purified as described (16) .
Thin layer chromatograRhy (TLC) . Purity of all compounds was determined by TLC on aluminum-backed silica gel plates (Merck) with 10% methanol in chloroform as eluant. Plates were developed by immersion in a solution of 5% anisaldehyde and 1 M sulfuric acid in ethanol, followed by heating on a hotplate. Rf values for the compounds in this system were: 0.33 [1] , 0.47 [2] , 0.52 [3] , 0.73 [4] , 0.52 [5] , 0.61 [6] and 0.27 [7] . As little as 0.01% of aphidicolin could be detected visually in the presence of any other derivative.
5108
DNA polymerases. DNA polymerase a from HeLa cells (17) and from Chinese hamster ovary (CHO) cells (18) and DNA polymerase III from L subtilis (19) were isolated as described. Reverse transcriptase from avian myeloblastosis virus (AMV RT) was obtained from Life Sciences Inc., St. Petersburg, FL. Polymerase assays. DNA polymerase assays were done as reported by Khan and Brown (18) . Assays typically measured acid-precipitable radioactivity incorporated into DNase-activated calf thymus DNA in the absence of the competitive substrate dCTP ("truncated assay"), and in the presence of 50 pM dGTP, dATP Inhibitor stock solutions were prepared in dimethylsulfoxide and diluted into enzyme assay mixtures; the solvent (<5Z) had no effect on the polymerase control assays.
RESULTS AND DISCUSSION
Inhibition of DNA polymerase a by aphidicolin derivatives.
Aphidicolin [1] Table) . Our observation of potent inhibition of DNA polymerase a by 2 is consistent with the report of Haraguchi et al. (14) [7] , was inactive against CHO DNA polymerase a at concentrations up to 100 pM (Table) .
Recently, 7 was also reported to be inactive against the KB cell enzyme (15) . Although this result indicates a high degree of stereospecificity of interaction of this part of aphidicolin with DNA polymerase a, the 3p-OH group does not appear to be essential for activity: for example, 3-deoxyaphidicolin, lacking the relevant hydroxyl group, was a potent inhibitor (Ki -1.3 uM) of the sea urchin enzyme (14) . In addition, both 3-deoxyaphidicolin and the 3-oxo derivative were reported to have "one-third" of the activity of 1 against the KB cell DNA polymerase a (15). Our results for compounds 2, 5 and 6 and the results from the literature cited above for the 3-deoxy and 3-oxo derivatives of aphidicolin clearly show that neither intact functional end of 1 is absolutely required for expression of DNA polymerase a inhibition. Simultaneous blocking of both ends of 1 (compounds 3 and 4) did, however, completely abolish inhibitory activity. Active derivatives are competitive with dCTP. We questioned if alterations of 1 might have produced active compounds that inhibited DNA polymerase a with different kinetics. In assays of HeLa DNA polymerase a under truncated, dCTP-deficient conditions, addition of 0.5 mM of both dGTP and dATP caused no decrease in inhibition by 1, 2, 5 or 6 at concentrations that inhibited the enzyme by 80-90%. However, addition of 0.5 mM dCTP in these assays completely reversed inhibition (results not shown).
Substantially the same results were obtained with the CHO enzyme for 1, 2 and 5 by classical kinetic analysis. As summarized in the Table and 
CONCLUSIONS
The results reported in this paper and those of related papers (14,15) suggest that 1 binds via both functional (hydroxylated) ends to two sites on DNA polymerase a, at least one of which is a site that binds dCTP, probably as a substrate. Either polar end of the molecule can be modified, but not both, and the resulting compounds can retain strong to moderate ability to bind and inhibit DNA polymerase a.
Modifications of 1 reported in this paper did not alter the kinetics of inhibition by active compounds, nor did any of the derivatives inhibit enzymes that are normally resistant to 1. Acetylation of the 17-OH group at the "upper end" of 1 (see structure) decreased activity 10-fold, whereas removal of the 17-carbon, leaving 16-oxo or 16-(H2) groups, decreased activity an additional 10-fold, suggesting the loss of hydrogen bonding interactions that may stabilize the aphidicolin:enzyme complex.
Specific interactions of this part of aphidicolin with enzyme are, therefore, probably not crucial to its binding, and inactivity of compounds bearing 17-substituents more bulky than acetyl (15) may result from steric repulsion. The "lower end" of 1, in contrast, cannot tolerate either a bulky substituent (compounds 3 and 4) or a change in configuration at C-3 (compound 7). Paradoxically, activity is little affected by oxidation of the 3-OH group, according to published results (15), or to its complete removal: the latter compound, 3-deoxyaphidicolin, was reported to be both a potent inhibitor of sea urchin and HeLa DNA polymerase a and competitive only with dCTP (14) .
The observations that the inhibitory activity of compounds modified at the "upper end" was also competitive with dCTP and that a configurational change at C-3 abolished 5112 activity would argue that the "lower end" of the molecule is that region that occupies or overlaps with a dCTP binding site on DNA polymerase a.
